Tilray Brands and its medical cannabis division, Tilray Medical, continue to bring more good news for its operations. The world’s leading firm in the cannabis industry has announced that this division has been able to receive approval to market its Tilray-branded medical marijuana products in Poland. Residents in Poland and the European market, in general, continue to experience the company’s greatly expanded product offering.
Tilray’s Director of Strategy and Head of International Business Denise Faltischek commented. “I’m extremely proud of our team in Europe for once again expanding our approved authorization for Tilray Medical products across Europe. Tilray will continue to advocate for reasonable patient access to reliable and high-quality medical cannabis in Europe and countries around the world.”
Tilray Medical is recognized globally for being an international supplier at the top of the heap when it comes to medical cannabis products. The quality of its products is so good that they have even received EU-GMP certification in over 20 countries. This broad portfolio of products is based on famous compounds such as cannabidiol (CBD) and tetrahydrocannabinol (THC) and offer a high degree of reliability and trust.
Each has an unparalleled profile of terpenes and cannabinoids, which have been exhaustively selected to ensure that patients can enjoy the best benefits of the plant. In Poland, Tilray Medical has already moved several keys to secure various relevant partnerships with pharmaceutical companies.
The idea behind this strategic move is to distribute Tilray’s branded and non-branded medical cannabis products. Patients have the possibility to access medical cannabis prescriptions in Poland through their preferred physician.